1. Home
  2. IONS

IONS

Ionis Pharmaceuticals Inc.

Logo Ionis Pharmaceuticals Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-16-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).

Founded: 1989 Country:
United States
United States
Employees: N/A City: CARLSBAD
Market Cap: 6.3B IPO Year: 1991
Target Price: $58.00 AVG Volume (30 days): 1.1M
Analyst Decision: Buy Number of Analysts: 13
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.56 EPS Growth: N/A
52 Week Low/High: $34.32 - $54.44 Next Earning Date: 05-01-2024
Revenue: $787,647,000 Revenue Growth: 34.10%
Revenue Growth (this year): -17.97% Revenue Growth (next year): 21.97%

Share on Social Networks: